Predict your next investment

Venture Capital
pivotalbiovp.com

See what CB Insights has to offer

Investments

36

Portfolio Exits

14

Funds

4

Partners & Customers

1

Service Providers

1

About Pivotal bioVenture Partners

Pivotal bioVenture Partners is a venture capital firm whose investment strategy is centered on identifying biotechnology companies developing differentiated science from discovery to early clinical development with the potential to deliver transformative therapies.

Pivotal bioVenture Partners Headquarter Location

1700 Owens Street Suite 595

San Francisco, California, 94158,

United States

415-697-1002

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Pivotal bioVenture Partners News

Avalyn Pharma Secures $35.5M Series B

Apr 28, 2020

Avalyn Pharma Inc., a biopharmaceutical company focused on development of improved therapies for life threatening pulmonary diseases, today announced the completion of a $35.5 million Series B financing. The round was led by Norwest Venture Partners along with participation by new investor Pivotal bioVenture Partners, and existing investors F-Prime Capital, Novo Holdings A/S, RiverVest Venture Partners, and TPG Biotech. Concurrent with the financing, venture capitalists Robert Mittendorff, M.D. joined the Board of Directors. Avalyn has just finished enrollment in a clinical study of two-dose regimens of aerosolized pirfenidone (AP01) in patients with idiopathic pulmonary fibrosis (IPF). Proceeds from the Series B expand the company's pipeline and will support the launch of a Phase II/III trial of AP01 in chronic lung allograft dysfunction (CLAD), the most common form of graft failure which occurs in over 50% of lung transplant recipients within five years of transplant and leads to re-transplant or death. Additionally, funds will support a Phase I study of AP02, aerosolized nintedanib, a program entering clinical development after successful preclinical studies in two lung injury models. "Reformulating systemic drugs for targeted inhaled lung delivery has successfully improved the efficacy and decreased systemic adverse effects of corticosteroids and bronchodilators in both asthma and COPD, and of antibiotics in cystic fibrosis," said Dr. A. Bruce Montgomery, CEO of Avalyn Pharma. "Despite the 2014 approval of two oral antifibrotic therapies, IPF and other fibrotic lung diseases remain fatal diseases with substantial unmet needs. We hope to accomplish improved tolerability and efficacy with both aerosolized pirfenidone and nintedanib. We are pleased by the safety profile we have seen to date with aerosolized pirfenidone in nearly 100 patients." About Avalyn Pharma Clinical Need IPF and other fibrotic lung diseases are characterized by progressive scarring, reduced exercise capacity and ultimate death from respiratory failure and/or co-morbidities. IPF treatments are relatively new, with the first and only approvals coming in 2014: oral pirfenidone (Esbriet®) and oral nintedanib (Ofev®). Both medicines, while effective in slowing disease progression are associated with significant adverse effects that limit dosing and their full potential for efficacy. While these medicines are an important first step to treat IPF, a substantial unmet need remains for therapies with improved safety profiles and better efficacy as either stand-alone or add-on combination therapies in both IPF and other fibrotic lung diseases. CLAD is a common form of graft failure after lung transplant, leading to progressive loss of lung function resulting in re-transplant or death. CLAD occurs despite treatment with maximum systemic doses of multiple anti-rejection drugs and affects the small airways and lung tissue. There has been promising early data treating CLAD with oral pirfenidone, however, the full potential for effective treatment is limited by severe systemic adverse effects associated with oral dosing. The Inhaled Advantage Although pirfenidone has shown promise to slow IPF disease progression, it is a low potency drug requiring a very large oral dose to achieve efficacious lung levels. Unfortunately, oral delivery results in blood levels which cause substantial adverse effects and limit the delivered lung dose. In a Phase I single dose study of AP01, we have demonstrated the potential of aerosolized pirfenidone to improve both efficacy and safety. Inhalation of a dose of AP01 equivalent to 1/16 of the licensed oral dose delivered 35-fold higher peak lung levels of pirfenidone with minimal adverse effects. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

Pivotal bioVenture Partners Investments

36 Investments

Pivotal bioVenture Partners has made 36 investments. Their latest investment was in OncXerna Therapeutics as part of their Series C on March 3, 2022.

CBI Logo

Pivotal bioVenture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/4/2022

Series C

OncXerna Therapeutics

$30M

Yes

1

2/23/2022

Series B

Plexium

$102M

No

9

2/10/2022

Series B

Arkuda Therapeutics

$64M

Yes

18

11/29/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/29/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/4/2022

2/23/2022

2/10/2022

11/29/2021

11/29/2021

Round

Series C

Series B

Series B

Series A

Series C

Company

OncXerna Therapeutics

Plexium

Arkuda Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$30M

$102M

$64M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

9

18

10

10

Pivotal bioVenture Partners Portfolio Exits

14 Portfolio Exits

Pivotal bioVenture Partners has 14 portfolio exits. Their latest portfolio exit was Vigil Neuroscience on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

$99M

Public

7

10/1/2021

IPO

$99M

Public

3

7/29/2021

IPO

$99M

Public

4

2/5/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/16/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

10/1/2021

7/29/2021

2/5/2021

10/16/2020

Exit

IPO

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

7

3

4

10

10

Pivotal bioVenture Partners Fund History

4 Fund Histories

Pivotal bioVenture Partners has 4 funds, including Pivotal bioVenture Partners China USD Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/24/2018

Pivotal bioVenture Partners China USD Fund I

Early-Stage Venture Capital

Closed

$150M

1

3/19/2018

Pivotal bioVenture Partners Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Pivotal bioVenture Partners CNS Fund I

10

Pivotal bioVenture Partners Fund II

10

Closing Date

5/24/2018

3/19/2018

Fund

Pivotal bioVenture Partners China USD Fund I

Pivotal bioVenture Partners Fund I

Pivotal bioVenture Partners CNS Fund I

Pivotal bioVenture Partners Fund II

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$150M

$99M

Sources

1

10

10

10

Pivotal bioVenture Partners Partners & Customers

1 Partners and customers

Pivotal bioVenture Partners has 1 strategic partners and customers. Pivotal bioVenture Partners recently partnered with Chinook Therapeutics on December 12, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

12/3/2021

Licensor

Canada

News - Pivotal bioVenture Partners China Announces Formation of SanReno Therapeutics

SanReno Therapeutics is a joint venture with an investor syndicate led by Pivotal bioVenture Partners China and Frazier Healthcare Partners to develop , manufacture and commercialize kidney disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan , as well as Singapore , and Chinook Therapeutics , Inc. has granted SanReno Therapeutics exclusive rights to develop and commercialize atrasentan and BION-1301 in Greater China and Singapore .

1

Date

12/3/2021

Type

Licensor

Business Partner

Country

Canada

News Snippet

News - Pivotal bioVenture Partners China Announces Formation of SanReno Therapeutics

SanReno Therapeutics is a joint venture with an investor syndicate led by Pivotal bioVenture Partners China and Frazier Healthcare Partners to develop , manufacture and commercialize kidney disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan , as well as Singapore , and Chinook Therapeutics , Inc. has granted SanReno Therapeutics exclusive rights to develop and commercialize atrasentan and BION-1301 in Greater China and Singapore .

Sources

1

Pivotal bioVenture Partners Service Providers

1 Service Provider

Pivotal bioVenture Partners has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Pivotal bioVenture Partners Team

4 Team Members

Pivotal bioVenture Partners has 4 team members, including current Managing Partner, Peter T. Bisgaard.

Name

Work History

Title

Status

Peter T. Bisgaard

Managing Partner

Current

Vincent Cheung

Managing Partner

Current

Rob Hopfner

Bay City Capital

Managing Partner

Current

Tracy Saxton

Frazier Healthcare Partners, Roche Venture Fund, SV Health Investors, UCSF Foundation, Geron, Threshold Pharmaceuticals, and Amgen

Managing Director

Former

Name

Peter T. Bisgaard

Vincent Cheung

Rob Hopfner

Tracy Saxton

Work History

Bay City Capital

Frazier Healthcare Partners, Roche Venture Fund, SV Health Investors, UCSF Foundation, Geron, Threshold Pharmaceuticals, and Amgen

Title

Managing Partner

Managing Partner

Managing Partner

Managing Director

Status

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.